More than 100 plaintiffs with cases pending in Pennsylvania federal court over claims that the diabetes drug Invokana caused kidney damage are challenging the drugmaker’s efforts to move those cases into a recently-established multidistrict litigation in New Jersey.
Drugmakers Janssen Pharmaceuticals recently filed a motion seeking to stay and then transfer or dismiss 106 cases that had been filed in Pennsylvania state court and later removed to the U.S. District Court for the Eastern District of Pennsylvania. The plaintiffs responded to those efforts Monday, arguing that the transfer would go against “virtually all of” the factors courts should consider.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
